Read by QxMD icon Read


Maciej Lesiak, Sylwia Zawada-Iwańczyk, Magdalena Łanocha, Aneta Klotzka, Michał Lesiak
Bioresorbable scaffolds (BRS) have been introduced to clinical practice to avoid some limitations associated with the presence of permanent metal prostheses in coronary arteries. Due to elimination of the natural vasomotion of the vessel and flow disturbance, stents impair endothelial function, increasing the risk of adverse events such as late and very late thrombosis or accelerated neoatherosclerosis. Additionally, the presence of metallic stents hinders non-invasive imaging of coronaries and may exclude the possibility of bypass graft anastomosis within the stented segment...
March 15, 2018: Minerva Cardioangiologica
Fernando Alfonso, Marcos García-Guimaraes, Teresa Bastante, Esther González-Bartol, Javier Cuesta, Fernando Rivero
No abstract text is available yet for this article.
March 13, 2018: Coronary Artery Disease
H Little, E Themistou, S A Clarke, E Cunningham, F Buchanan
The original version of this article unfortunately contained a mistake. E. Themistou was missing from the author group and so is now included with this erratum.
March 9, 2018: Journal of Materials Science. Materials in Medicine
Gentil Barreira, J Ribamar Costa, Ricardo Costa, Rodolfo Staico, Daniel Chamie, Juliano R Slhessarenko, Luiz Fernando Tanajura, Andrea Abizaid, Amanda Sousa, Alexandre Abizaid
INTRODUCTION: Bioresorbable coronary scaffolds (BRS) have been developed to increase the late safety of coronary angioplasty by providing transitory coronary support and then being fully incorporated to the vessel wall. In the present trial, we sought to evaluate the performance and changes over time in the DESolve™ novolimus-eluting BRS using serial intravascular ultrasound (IVUS) in patients submitted to percutaneous coronary interventions. METHODS: Single-center, prospective, non-randomized study involving 17 consecutive patients submitted to implantation of the DESolve™ scaffold and serial evaluated with IVUS at different time points (post procedure, 6 and 18 months)...
March 9, 2018: Catheterization and Cardiovascular Interventions
Klaudia Pluta, Agnieszka Sobczak-Kupiec, Olga Półtorak, Dagmara Malina, Bożena Tyliszczak
Calcium phosphates (CPs) constitute attractive materials of biomedical applications. Among them particular attention is devoted to bioactive hydroxyapatite (HAp) and bioresorbable tricalcium phosphate (TCP) that possess ability to bind to living bones and can be used clinically as important bone substitutes. Notably, in vivo bone bioactivity can be predicted from apatite formation of bone immersed in SBF fluids. Thus, analyses of behavior of calcium phosphates immersed in various bio fluids are of great importance...
March 9, 2018: Journal of Biomedical Materials Research. Part A
V Bonito, A I P M Smits, O J G M Goor, B D Ippel, A Driessen-Mol, T J A G Münker, A W Bosman, T Mes, P Y W Dankers, C V C Bouten
Hallmark of the in situ tissue engineering approach is the use of bioresorbable, synthetic, acellular scaffolds, which are designed to modulate the inflammatory response and actively trigger tissue regeneration by the body itself at the site of implantation. Much research is devoted to the design of synthetic materials modulating the polarization of macrophages, which are essential mediators of the early stages of the inflammatory response. Here, we present a novel method for the functionalization of elastomers based on synthetic peptide chemistry, supramolecular self-assembly, and immobilization of heparin and interleukin 4 (IL-4), which is known to skew the polarization of macrophages into the wound healing "M2" phenotype...
March 5, 2018: Acta Biomaterialia
Giuseppe Tarantini, Giulia Masiero, Alberto Barioli, Valeria Paradies, Georgios Vlachojannis, Paola Tellaroli, Bernardo Cortese, Gaetano di Palma, Attilio Varricchio, Alfonso Ielasi, Bruno Loi, Giuseppe Steffenino, Daisuke Ueshima, Marco Mojoli, Pieter Smits
BACKGROUND: Patients with small vessel disease (SVD) are at higher risk of adverse events after PCI compared to non-SVD patients. In this subset, the use of bioresorbable vascular scaffolds (BVS) has raised particular concern. OBJECTIVE: We aimed to compare outcomes of Absorb BVS versus a 2nd-generation metallic everolimus-eluting stents (EES) in the SVD setting, by pooling patients from three large, prospective studies. METHODS: Patients with SVD (reference vessel diameter ≤2...
March 7, 2018: Catheterization and Cardiovascular Interventions
Antonio H Frangieh, Milosz Jaguszewski, Yoichi Imori, Slayman Obeid, Christian Templin
No abstract text is available yet for this article.
2018: Cardiology Journal
Christian-Hendrik Heeger, Anne-Sophie Schedifka, Felix Meincke, Tobias Spangenberg, Hendrick Wienemann, Felix Kreidel, Karl-Heinz Kuck, Alexander Ghanem, Martin W Bergmann
BACKGROUND: Suboptimal implantation of everolimus-eluting bioresorbable vascular scaffolds (EE-BVS) leading to strut malapposition and lack of neointima coverage has been hypothesized to be linked to late BVS-thrombosis. Optical coherence tomography (OCT) allows assessing subtle differences in BVS-healing. We aimed to link 6-months OCT-data on EE-BVS coverage and malapposition to implantation technique and clinical outcome. METHODS: Twenty-nine consecutive EE-BVS-patients were included...
March 7, 2018: Cardiology Journal
Holger Nef, Jens Wiebe, Niklas Boeder, Oliver Dörr, Timm Bauer, Karl-Eugen Hauptmann, Azeem Latib, Antonio Colombo, Dieter Fischer, Tanja Rudolph, Nicolas Foin, Gert Richardt, Christian Hamm
OBJECTIVES: To date, experience with bioresorbable scaffolds (BRS) that elute agents other than everolimus is limited. Thus, a post-marketing clinical follow-up study was conducted to evaluate the continued safety and effectiveness of the DESolve® NOVOLIMUS™ Eluting BRS as treatment for patients with stable coronary artery disease. BACKGROUND: The DESolve BRS combines a poly-l-lactide-based backbone with a biodegradable polylactide-based polymer and Novolimus, a macrocyclic lactone mTOR inhibitor...
March 6, 2018: Catheterization and Cardiovascular Interventions
Xucheng Lv, Li Shen, Yizhe Wu, Lei Ge, Jiahui Chen, Jiasheng Yin, Rui Wang, Meng Ji, Bin Hong, Junbo Ge
The objectives of this study are to assess the healing score (HS) and neointimal thickness of the Xinsorb scaffold, and explore the relationships between the implanted patterns, neointimal thickness, and HS. The Xinsorb bioresorbable sirolimus-eluting scaffold is the first domestically designed and fabricated bioresorbable scaffold in China. The 6-month follow-up found it to be safe and effective in the treatment of single de novo coronary lesions. The Xinsorb scaffolds were implanted in 30 patients with symptomatic ischemic coronary disease...
February 28, 2018: International Journal of Cardiovascular Imaging
Yohei Sotomi, Yoshinobu Onuma, Shengnan Liu, Taku Asano, Jeroen Eggermont, Yuki Katagiri, Rafael Cavalcante, Robbert J de Winter, Joanna J Wykrzykowska, Salvatore Brugaletta, Lorenz Räber, Manel Sabaté, Stephan Windecker, Jouke Dijkstra, Patrick W Serruys
AIMS: We aimed to assess possible difference of the neointimal quality after everolimus-eluting bioresorbable scaffold (BVS) implantation in comparison with cobalt chromium everolimus-eluting scaffold (CoCr-EES) by optical frequency domain imaging (OFDI). METHODS AND RESULTS: This study is a post-hoc analysis of TROFI II trial assessing neointimal quality 6-month after the implantation of BVS(N=82) and CoCr-EES(N=87) in STEMI patients. Neointimal light property analysis by OFDI full-automatically computed light attenuation, backscatter and light intensity for superficial and deep neointima...
February 27, 2018: EuroIntervention
Pei-Jiang Wang, Nicola Ferralis, Claire Conway, Jeffrey C Grossman, Elazer R Edelman
Polymer-based bioresorbable scaffolds (BRS) seek to eliminate long-term complications of metal stents. However, current BRS designs bear substantially higher incidence of clinical failures, especially thrombosis, compared with metal stents. Research strategies inherited from metal stents fail to consider polymer microstructures and dynamics--issues critical to BRS. Using Raman spectroscopy, we demonstrate microstructural heterogeneities within polymeric scaffolds arising from integrated strain during fabrication and implantation...
February 26, 2018: Proceedings of the National Academy of Sciences of the United States of America
Marta Musioł, Sebastian Jurczyk, Michał Kwiecień, Anna Smola-Dmochowska, Marian Domański, Henryk Janeczek, Jakub Włodarczyk, Magdalena Klim, Joanna Rydz, Michał Kawalec, Michał Sobota
The semicrystalline poly(L-lactide) (PLLA) belongs to the materials with shape memory effect (SME) and as a bioresorbable and biocompatible polymer it have found many applications in medical and pharmaceutical field. Assessment of the SME impact on the polymer degradation profile plays crucial role in applications such as drug release systems or in regenerative medicine. Herein, the results of in vitro degradation studies of PLLA samples after SME full test cycle are presented. The samples were loaded and deformed in two manners: progressive and non-progressive...
February 19, 2018: Journal of the Mechanical Behavior of Biomedical Materials
Bryant Heimbach, Beril Tonyali, Dianyun Zhang, Mei Wei
Bone fractures are some of the most common injuries annually, and many require a fixation device to help properly heal. The present study focuses on developing a bioresorbable composite that has high strength and stiffness for bone fixation applications. To achieve this, a design of experiments was performed, testing the effect of long fiber reinforcement type, matrix type, matrix amount, and particle reinforcement amount on the flexural properties of the composite. Based on these results, the ideal resorbable long fiber reinforcement, particle reinforcement, and matrix material are degummed silk fibroin, hydroxyapatite, and polylactic acid, respectively...
February 19, 2018: Journal of the Mechanical Behavior of Biomedical Materials
Michael Joner, Philipp Ruppelt, Philine Zumstein, Capucine Lapointe-Corriveau, Guy Leclerc, Anna Bulin, Maria Isabel Castellanos, Eric Wittchow, Michael Haude, Ron Waksman
AIMS: Because vascular restoration therapy using bioresorbable vascular scaffolds (BRS) remains an appealing concept to restore vasoreactivity, understanding of biodegradation remains paramount during preclinical testing. METHODS AND RESULTS: Qualitative characterization of biodegradation was performed in 41 DREAMS 1G up to 3 years, while degradation kinetics were acquired in 54 DREAMS 2G implanted into porcine coronary arteries for 28, 90 and 180 days, 1 and 2 years...
February 20, 2018: EuroIntervention
Dan Liu, Daguo Mi, Tuanjie Zhang, Yanping Zhang, Junying Yan, Yaxian Wang, Xuefeng Tan, Ying Yuan, Yumin Yang, Xiaosong Gu, Wen Hu
The repair of peripheral nerve laceration injury to obtain optimal function recovery remains a big challenge in the clinic. Misdirection of regenerating axons to inappropriate target, as a result of forced mismatch of endoneurial sheaths in the case of end-to-end nerve anastomosis or nerve autografting, represents one major drawback that limits nerve function recovery. Here we tested whether tubulation repair of a nerve defect could be beneficial in terms of nerve regeneration accuracy and nerve function. We employed sequential retrograde neuronal tracing to assess the accuracy of motor axon regeneration into the tibial nerve after sciatic nerve laceration and entubulation in adult Sprague-Dawley rats...
February 21, 2018: Scientific Reports
Christian Oliver Fallesen, Lisbeth Antonsen, Per Thayssen, Lisette Okkels Jensen, Pil Hyung Lee, Seung-Whan Lee, Seung-Jung Park, Elisabetta Moscarella, Giosafat Spitaleri, Salvatore Brugaletta
No abstract text is available yet for this article.
February 20, 2018: EuroIntervention
Anne Venkata Ganeshkumar, Rushikesh Sambhaji Patil, Irfan Khan Hamid
BACKGROUND AND OBJECTIVE: Studies conducted across the world have reported that the rates of major adverse cardiac events (MACE) following the use of bioresorbable vascular scaffolds (BVS) are comparable to that noted with traditional drug eluting stents (DES). However, there is limited data on the immediate and medium-term clinical outcomes following the use of the Absorb BVS (Abbott Vascular, Santa Clara, SA) in the Indian context. This study was conducted to determine real-world evidence on the immediate and medium-term clinical outcomes in all patients undergoing percutaneous coronary intervention (PCI) with the Absorb BVS...
January 2018: Indian Heart Journal
Young Bin Song, Seok Kyu Oh, Ju-Hyeon Oh, Eul-Soon Im, Deok-Kyu Cho, Byung Ryul Cho, Jong-Young Lee, Joo Myung Lee, Taek Kyu Park, Jeong Hoon Yang, Jin-Ho Choi, Seung-Hyuck Choi, Sang Hoon Lee, Hyeon-Cheol Gwon, Joo-Yong Hahn
BACKGROUND AND RATIONALE: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), but these benefits come at the expense of increased risk of bleeding when compared with aspirin monotherapy. It is unclear whether P2Y12 inhibitor monotherapy might maintain anti-ischemic efficacy while reducing the bleeding risk compared with DAPT after implantation of the current generation of drug-eluting stents (DES)...
March 2018: American Heart Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"